Send to

Choose Destination
See comment in PubMed Commons below
Urol Clin North Am. 2012 Nov;39(4):517-31. doi: 10.1016/j.ucl.2012.07.008. Epub 2012 Sep 1.

Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor.

Author information

  • 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.


Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death in Western countries. Most patients with prostate cancer respond to initial androgen deprivation therapy but eventually progress to castration-resistant prostate cancer (CRPC). Although androgen receptor signaling remains the main driver in CRPC, a growing body of evidence suggests that other pathways are involved in this progression. This article reviews the preclinical data and current status of clinical trials therapeutically targeting tubulin, DNA repair, molecular chaperones such as CLU and Hsp27, tyrosine kinases, and DNA repair.

Copyright © 2012 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk